Eli Lilly eyes Kelonia Therapeutics in $7B deal with $3.25B to be paid up front, and before investors could buy. How to get in early on market moves
Biotech is big business.
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks ...
ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma
Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ...
UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
June 9 (Reuters) - British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion to boost its lung cancer portfolio. The all-cash deal values Nuvalent ...
Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?
Infectious disease could fuel Eli Lilly's next growth phase.
FiercePharma
The Oral GLP-1 Tracker: Week 1 of Lilly's Foundayo launch
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...
India West
FDA Flags Indian Drug Maker Lupin’s NJ Plant
SOMERSET, NJ -Major drug maker Lupin said on April 18 that the US Food and Drug Administration (USFDA) has issued a ‘Form 483’ with three observations to the company’s manufacturing facility in ...